Kevin Dunsmoor, DO
Internal Medicine · Las Vegas, NVNPI 1992963664
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $229,103 of the $241,375 with a category attached, or 94.9%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 95.0% of it on its own, with 50 other manufacturers making up the rest. Among internal medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 895 payments — averaging $269.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$229K
- AbbVie$2K
- Novo Nordisk$2K
- GSK$925
- AstraZeneca$765
- Pfizer$750
- plus $6K from 45 others
What the payments were for
- Consulting fees$229,10395%
- Travel & lodging$1400%
- Food & beverage$12,0325%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$241,375 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $108,027 |
| MounjaroTirzepatide | 96 | $103,322 |
| JardianceEmpagliflozin | 68 | $65,241 |
| EliquisApixaban | 59 | $64,558 |
| RybelsusSemaglutide | 36 | $41,763 |
| FarxigaDapagliflozin Propanediol | 59 | $41,230 |
| TrulicityDulaglutide | 28 | $38,398 |
| MyrbetriqMirabegron | 36 | $34,112 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $29,363 |
| SynjardyEmpagliflozin/Metformin Hcl | 17 | $25,300 |
| VascepaIcosapent Ethyl | 21 | $15,600 |
| JanuviaSitagliptin Phosphate | 17 | $14,887 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $13,697 |
| XareltoRivaroxaban | 12 | $13,579 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $9,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,532 | $149,790143 claims |
| Lilly USA, LLCMounjaro, Trulicity | $458 | $141,720124 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Spiriva Respimat | $395 | $126,786134 claims |
| PfizerEliquis | $750 | $64,55859 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $765 | $57,94686 claims |
| Astellas Pharma US IncMyrbetriq | $627 | $34,11236 claims |
| MerckJanuvia | $147 | $14,88717 claims |
| Johnson & JohnsonXarelto | $602 | $13,57912 claims |
| AbbVieSynthroid, Armour Thyroid | $2,148 | $4,60163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
- Henry WangLas Vegas$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.